Psychometric Study of the Social Responsiveness Scale in Phelan-McDermid Syndrome - PubMed
. 2020 Aug;13(8):1383-1396.
doi: 10.1002/aur.2299. Epub 2020 May 14.
Alan Weinberg 2 , Jonathan Templin 3 , Cristan Farmer 4 , Alison Durkin 5 , Jordana Weissman 5 , Paige Siper 5 , Jennifer Foss-Feig 5 , Maria Del Pilar Trelles 5 , Jonathan A Bernstein 6 , Joseph D Buxbaum 5 7 8 , Elizabeth Berry-Kravis 9 10 11 , Craig M Powell 12 13 , Mustafa Sahin 14 15 , Latha Soorya 16 , Audrey Thurm 4 , Alexander Kolevzon 5 17 ; Developmental Synaptopathies Consortium 15
Affiliations
- PMID: 32406614
- PMCID: PMC8103889
- DOI: 10.1002/aur.2299
Psychometric Study of the Social Responsiveness Scale in Phelan-McDermid Syndrome
Kellie Gergoudis et al. Autism Res. 2020 Aug.
Abstract
The Social Responsiveness Scale-2 (SRS-2) is a quantitative measure used to characterize symptoms of autism spectrum disorder (ASD). However, research suggests that SRS-2 scores are significantly influenced by language ability and intellectual disability (ID). Efforts to refine the SRS-2 by Sturm, Kuhfeld, Kasari, and Mccracken [Journal of Child Psychology and Psychiatry, 58(9), 1053-1061] yielded a shortened form, yet its psychometric properties in populations with severe ID remain unknown. This study aims to examine the psychometric properties of the SRS-2 in Phelan-McDermid syndrome (PMS), a genetic condition associated with ASD and ID, thereby guiding score interpretation in this population and future development of targeted scales. Analyses, including Item Response Theory (IRT), were conducted on a sample of individuals with PMS (n = 91) recruited at six sites nationally. Psychometric properties evaluated include measures of reliability (internal consistency, test-retest reliability) and validity (structural, construct, content). While both SRS-2 forms are reliable, the shortened SRS-2 shows superior validity to the full SRS-2 for measuring ASD symptoms in PMS. On IRT analysis, the shortened SRS-2 shows excellent discrimination and precisely evaluates respondents across a wide range of ASD symptomatology but interpretation is limited by uncertain content validity and small sample size. The shortened SRS-2 shows some promise for use in PMS, but future refinements and additions are needed to develop items that are tailored to identify ASD in children with severe ID and specifically PMS. LAY SUMMARY: This study determined that a shortened form of the Social Responsiveness Scale, Second Edition (SRS-2) shows both promise and limitations for the characterization of autism symptomatology in individuals with Phelan-McDermid syndrome (PMS), a population characterized by intellectual disability (ID). Caution should be used when interpreting SRS-2 scores in individuals with ID and future research should modify existing items and develop new items to improve the SRS-2's ability to accurately characterize autism symptomatology in PMS. Autism Res 2020, 13: 1383-1396. © 2020 International Society for Autism Research, Wiley Periodicals, Inc.
Keywords: Item Response Theory; Phelan-McDermid syndrome; autism spectrum disorder; behavioral measures; intellectual disability.
© 2020 International Society for Autism Research and Wiley Periodicals LLC.
Figures

Graphical representation of item discrimination and difficulty parameters.

Information curves of Sturm’s SRS-2 as a function of latent trait (autism symptomatology) Level. (A) Total information curve and (B) item information curves for items 7, 11, 15, 22, 23, 30, 41, 51, 56, and 65.

Item characteristic curves for selected items. (A) Item 7 and (B) Item 16 (all response categories) as a function of F1.
Similar articles
-
Oberman LM, Boccuto L, Cascio L, Sarasua S, Kaufmann WE. Oberman LM, et al. Orphanet J Rare Dis. 2015 Aug 27;10:105. doi: 10.1186/s13023-015-0323-9. Orphanet J Rare Dis. 2015. PMID: 26306707 Free PMC article.
-
Gait Abnormalities in Children with Phelan-McDermid Syndrome.
Frank Y, Levy T, Lozano R, Friedman K, Underwood S, Kostic A, Walker H, Kolevzon A. Frank Y, et al. J Child Neurol. 2023 Dec;38(13-14):665-671. doi: 10.1177/08830738231204395. Epub 2023 Oct 18. J Child Neurol. 2023. PMID: 37849292
-
Samogy-Costa CI, Varella-Branco E, Monfardini F, Ferraz H, Fock RA, Barbosa RHA, Pessoa ALS, Perez ABA, Lourenço N, Vibranovski M, Krepischi A, Rosenberg C, Passos-Bueno MR. Samogy-Costa CI, et al. J Neurodev Disord. 2019 Jul 18;11(1):13. doi: 10.1186/s11689-019-9273-1. J Neurodev Disord. 2019. PMID: 31319798 Free PMC article.
-
Phelan-McDermid Syndrome and SHANK3: Implications for Treatment.
Costales JL, Kolevzon A. Costales JL, et al. Neurotherapeutics. 2015 Jul;12(3):620-30. doi: 10.1007/s13311-015-0352-z. Neurotherapeutics. 2015. PMID: 25894671 Free PMC article. Review.
-
The Neurological Manifestations of Phelan-McDermid Syndrome.
Frank Y. Frank Y. Pediatr Neurol. 2021 Sep;122:59-64. doi: 10.1016/j.pediatrneurol.2021.06.002. Epub 2021 Jun 16. Pediatr Neurol. 2021. PMID: 34325981 Review.
Cited by
-
Understanding the relationship between cerebellar structure and social abilities.
Elandaloussi Y, Floris DL, Coupé P, Duchesnay E, Mihailov A, Grigis A, Bègue I, Victor J, Frouin V, Leboyer M, Houenou J, Laidi C. Elandaloussi Y, et al. Mol Autism. 2023 May 15;14(1):18. doi: 10.1186/s13229-023-00551-8. Mol Autism. 2023. PMID: 37189195 Free PMC article.
-
Characterizing the autism spectrum phenotype in DYRK1A-related syndrome.
Kurtz-Nelson EC, Rea HM, Petriceks AC, Hudac CM, Wang T, Earl RK, Bernier RA, Eichler EE, Neuhaus E. Kurtz-Nelson EC, et al. Autism Res. 2023 Aug;16(8):1488-1500. doi: 10.1002/aur.2995. Epub 2023 Jul 27. Autism Res. 2023. PMID: 37497568 Free PMC article.
-
GENE TARGET: A framework for evaluating Mendelian neurodevelopmental disorders for gene therapy.
Chopra M, Modi ME, Dies KA, Chamberlin NL, Buttermore ED, Brewster SJ, Prock L, Sahin M. Chopra M, et al. Mol Ther Methods Clin Dev. 2022 Aug 29;27:32-46. doi: 10.1016/j.omtm.2022.08.007. eCollection 2022 Dec 8. Mol Ther Methods Clin Dev. 2022. PMID: 36156879 Free PMC article. Review.
-
Storch EA, Schneider SC, Olsen SM, Ramirez AC, Berry LN, Goin-Kochel RP, McNeel M, Candelari AE, Guzick AG, Cepeda SL, Weinzimmer S, Voigt RG, Quast T, Goodman WK, Salloum A. Storch EA, et al. J Autism Dev Disord. 2024 Jan;54(1):93-108. doi: 10.1007/s10803-022-05775-w. Epub 2022 Oct 14. J Autism Dev Disord. 2024. PMID: 36239830 Free PMC article. Clinical Trial.
-
Wright D, Kenny A, Mizen LAM, McKechanie AG, Stanfield AC. Wright D, et al. J Autism Dev Disord. 2025 Jan;55(1):297-309. doi: 10.1007/s10803-023-06162-9. Epub 2023 Dec 6. J Autism Dev Disord. 2025. PMID: 38055183 Free PMC article.
References
-
- Aman MG, & Singh NN (1986). Aberrant behavior checklist. East Aurora, NY: Slosson.
-
- American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (DSM-5®). Philadelphia, PA: American Psychiatric Publishing.
-
- Anagnostou E, Soorya L, Brian J, Dupuis A, Mankad D, Smile S, & Jacob S (2014). Intranasal oxytocin in the treatment of autism spectrum disorders: A review of literature and early safety and efficacy data in youth. Brain Research, 1580, 188–198. - PubMed
-
- Baker FB (2002). The basics of item response theory (Vol. 2). College Park, MD: ERIC Clearinghouse on Assessment and Evaluation.